Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

NICE issues guidance on boceprevir and telaprevir for hepatitis C

Published: 30 April 2012
New guidance issued by NICE

The National Institute for Health and Clinical Excellence (NICE) has issued guidance to the health service on the use of boceprevir and telaprevir for the treatment of patients with hepatitis C, based on reports produced by SHTAC.

 NICE has issued guidance to the health service in England and Wales recommending use of boceprevir and telaprevir as treatment options for chronic hepatitis C in adults with compensated liver disease. NICE's guidance is based on two Evidence Review Group (ERG) reports conducted by SHTAC which reviewed clinical-effectiveness and cost-effectiveness data supplied by the drug manufacturers.

Both drugs are from a class of drugs known as protease inhibitors, and have been studied in the treatment of a sub-group of patients who have harder to treat hepatitis C genotype 1. Boceprevir or telaprevir can be added to pegylated interferon alfa and ribavirin, the existing standard of treatment. The ERG reports are available from the Health Technology Assessment programme website (click here for the boceprevir report, and here for the telaprevir report).

For details of SHTAC's previous research on hepatitis visit the Research page.

 

Privacy Settings